Get the Stockscreener App
14.28
0.07%
0.010
Anika Therapeutics Inc stock is traded at $14.28, with a volume of 91,715.
It is up +0.07% in the last 24 hours and up +31.61% over the past month.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
See More
Previous Close:
$14.27
Open:
$14.12
24h Volume:
91,715
Relative Volume:
0.62
Market Cap:
$191.36M
Revenue:
$112.82M
Net Income/Loss:
$-9.98M
P/E Ratio:
-18.82
EPS:
-0.7588
Net Cash Flow:
$4.36M
1W Performance:
-1.59%
1M Performance:
+31.61%
6M Performance:
+57.44%
1Y Performance:
-7.81%
1-Day Range:
$14.10
$14.36
1-Week Range:
$13.70
$14.55
52-Week Range:
$7.8701
$15.79
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.28 | 191.36M | 112.82M | -9.98M | 4.36M | -0.7588 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Anika Therapeutics (ANIK) SVP Ian McLeod granted RSUs and PPSARs - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
If You Invested $1,000 in Anika Therapeutics Inc (ANIK) - Stock Titan
ANIK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regenerative Medicine Market Is Going to Boom | Anika Therapeutics, Inc. and Arthrex - openPR.com
Anika Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Anika Therapeutics (ANIK) EVP reports RSU vesting and tax share withholding - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) CEO adds shares via RSU vesting and award - Stock Titan
Anika Therapeutics (ANIK) director vests RSUs, withholds shares for taxes - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) SVP gains shares via RSUs, covers taxes with stock - Stock Titan
Precision Trading with Anika Therapeutics Inc. (ANIK) Risk Zones - Stock Traders Daily
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving Average – What’s Next? - Defense World
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Anika Therapeutics falls after its completes divestiture of Parcus Medical business - TradingView
Anika Therapeutics (ANIK) EVP’s RSUs Vest with Shares Withheld for Taxes - Stock Titan
Anika Therapeutics (ANIK) director nets RSU shares after tax withholding - Stock Titan
Anika Therapeutics (ANIK) SVP RSUs vest; 639 shares withheld for taxes - Stock Titan
Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations - MSN
Anika Therapeutics Earnings Call Signals Cautious Rebound - TipRanks
Jobs Data: Will Anika Therapeutics Inc. (AKP) stock gain from lower interest ratesWeekly Loss Report & Capital Efficiency Focused Ideas - Naître et grandir
Anika Therapeutics (NASDAQ:ANIK) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Bank Watch: Is Anika Therapeutics Inc still a buy after recent gains2025 AllTime Highs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Published on: 2026-03-07 10:02:22 - baoquankhu1.vn
Trigran Investments Inc. Sells 415,296 Shares of Anika Therapeutics Inc. $ANIK - MarketBeat
Technical Reactions to ANIK Trends in Macro Strategies - Stock Traders Daily
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Anika Therapeutics Is Cheap, But FDA Decisions And OEM Pricing Still Rule - Finimize
Anika Therapeutics debuts Integrity and highlights portfolio at AAOS - Traders Union
Anika Therapeutics 2025 10-K: Revenue $112.8M, Diluted Loss per Share $(0.70) - TradingView
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference - Yahoo Finance
Anika Therapeutics, Inc. (ANIK) Presents at 2026 CG Musculoskeletal ConferenceSlideshow - Seeking Alpha
ANIK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) sharpens HA strategy with asset sales - Stock Titan
Does Anika Therapeutics, Inc. (ANIK) Have Momentum? - AAII
Anika Therapeutics Q4 Earnings Call Highlights - Defense World
Anika Therapeutics (NASDAQ:ANIK) Stock Price Expected to Rise, Barrington Research Analyst Says - Defense World
Anika Therapeutics (ANIK) Receives a Buy from B. Riley Securities - The Globe and Mail
ANIK | Anika Therapeutics Inc FinancialsIncome Statement - Quiver Quantitative
Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results - MarketBeat
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock - MarketBeat
ANIK: Barrington Research Raises Price Target to $17, Maintains 'Outperform' | ANIK Stock News - GuruFocus
Anika Therapeutics showcases Integrity benefits at ACFAS conference - Traders Union
Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating - marketscreener.com
B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating - marketscreener.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIK) 2026-02-27 - Seeking Alpha
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: - GuruFocus
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Earnings call transcript: Anika Therapeutics Q4 2025 results beat expectations - Investing.com
Anika Therapeutics (ANIK) Reports Consistent Q4 Revenue with Pro - GuruFocus
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):